A Waterford family is advocating for increased awareness surrounding a rare genetic disorder known as CACNA1E. Only 150 individuals globally are diagnosed with this mutation. Lorelei Dunn, a one-year-old resident of Waterford, Michigan, represents one of approximately 30 people worldwide with her specific genetic variation.
The Daily Struggle of Rare Disease Care
Daily life for the Dunn family involves a strict and complex medical regimen. Kayleigh Dunn, Lorelei’s mother, manages multiple medications that must be crushed and prepared for a feeding tube twice a day. This routine is necessary due to the severe complications caused by the disorder.
Lorelei suffers from a significant seizure disorder, severe hypotonia, and a lack of trunk support. These symptoms prevent her from holding her head up and make conventional nutrition impossible. The physical and emotional weight of this care is substantial. It requires constant attention and a high level of medical coordination.
Overcoming Barriers to Treatment
In May 2026, the family faced a critical threat to their access to care when their insurance coverage faced cancellation. The loss of that coverage would have forced a search for new medical providers. Finding specialists capable of handling such an rare case proved difficult.
The family struggled to identify a neurologist in Michigan willing to lead a case study for Lorelei’s treatment. The time commitment required for such specialized care is intense. They eventually secured a connection with a neurologist at University of Michigan Medicine.
This connection offered a potential pathway for gene therapy. After media coverage highlighted their situation earlier this year, the family successfully secured an extension on their insurance. That victory kept the door open for continued medical intervention.
The Necessity of Awareness
CACNA1E Awareness Day serves as a focal point for families like the Dunns to push for broader research. Increased awareness often dictates the speed and quality of medical advancements for rare mutations. The rarity of the condition makes patient advocacy the primary driver of funding and scientific interest.
Lorelei’s parents emphasize that she is not defined by her diagnosis despite the challenges. They maintain a public platform to share her story and seek support for her medical needs. The family continues to work toward a future where treatment options are more accessible.
The broader medical picture for ultra-rare conditions is slow. Clinical trials and case studies remain the main hope for families dealing with mutations that affect fewer than 200 people globally. Every story brought to public attention influences how medical institutions allocate resources and support families facing similar diagnostic landscapes.